Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 4/2021

01-04-2021 | Prostate Cancer | Letter to the Editor

In reply to Afkhami Ardekani M et al.

Authors: Franco Campostrini, MD, Alberto Buffoli, MD, Federica Foscarini, MD, Manuel Zorzi, MD

Published in: Strahlentherapie und Onkologie | Issue 4/2021

Login to get access

Excerpt

We thank Mahdieh Afkhami Ardekani et al. for their comments on our paper in discussion [1]. In this reply, we will only deal with late gastrointestinal (G1) toxicity after radical external radiotherapy (RT), while brachytherapy and postoperative RT would require separate dissertations. …
Literature
1.
Afkhami Ardekani M, Navaser M, Ghaffari H, Refahi S (2020) Letter to the editor on: F.Campostrini et al. “Association between acute histopathological changes of rectal walls and late radiation proctitis following radiotherapy for prostate cancer”. Strahlenther Onkol. https://​doi.​org/​10.​1007/​s0006-020-01719-4CrossRef
2.
Song DY, Herfarth KK, Uhl M, Eble MJ, Pinkawa M, van Triest B et al (2013) A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes. Int J Radiat Oncol Biol Phys 87:81–87CrossRef
3.
Karsh LI, Gross ET, Pieczonka CM, Aliotta PJ, Skomra CJ, Ponsky LE et al (2018) Absorbable hydrogel spacer use in prostate radiotherapy: a comprehensive review of phase 3 clinical trial published data. Urology 115:39–44CrossRef
4.
O’Brien PC, Hamilton CS, Denham JW, Gourlay R, Franklin CIV (2004) Spontaneous improvement in late rectal mucosal changes after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 58:75–80CrossRef
5.
Ippolito E, Deodato F, Macchia G, Massaccesi M, Digesù C, Pirozzi GA et al (2012) Early radiation-induced mucosal changes evaluated by proctoscopy: predictive role of dosimetric parameters. Radiother Oncol 104:103–108CrossRef
6.
Wachter S, Gerstner N, Goldner G, Pötzi R, Wambersie A, Pötter R (2000) Endoscopic scoring of late rectal mucosa damage after conformal radiotherapy for prostate carcinoma. Radiother Oncol 54:11–19CrossRef
7.
Wolff D, Stieler F, Welzel G, Lorenz F, Abo-Madyan Y, Mai S et al (2009) Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. Radiother Oncol 93:226–233CrossRef
8.
Campostrini F, Remo A, Astati L, Zorzi M, Capodaglio G, Buffoli A et al (2020) Association between acute histopathological changes of rectal walls and late radiation proctitis following radiotherapy for prostate cancer. Strahlenther Onkol 196:617–627CrossRef
9.
Uhl M, Herfarth K, Eble MJ, Pinkawa M, van Triest B, Kalisvaart R et al (2014) Absorbable hydrogel spacer use in men undergoing prostate cancer radiotherapy: 12 month toxicity and proctoscopy results of a prospective multicenter phase II trial. Radiat Oncol 9:96CrossRef
10.
Whalley D, Hruby G, Alfieri F, Kneebone A, Eade T (2016) SpaceOAR hydrogel in dose escalated prostate cancer radiotherapy: rectal dosimetry and late toxicity. Clin Oncol 28:e148–e154CrossRef
11.
Schörghofer A, Drerup M, Kunit T, Lusuardi L, Holzinger J, Karner J et al (2019) Rectum-spacer related acute toxicity—Endoscopy results of 403 prostate cancer patients after implantation of gel or balloon spacers. Radiat Oncol 4:47CrossRef
12.
Chapet O, Decullier E, Bin S, Faix A, Ruffion A, Jalade P et al (2015) Prostate hypofractionated radiation therapy with injection of hyaluronic acid: acute toxicities in a phase 2 study. Int J Radiat Oncol Biol Phys 91:730–736CrossRef
13.
Gez E, Cytron S, Yosef RB, London D, Corn BW, Alani S et al (2013) Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study. Radiat Oncol 8:96CrossRef
14.
van Lin ENJT, Kristinsson J, Philippens MEP, de Jong DJ, van der Vight LP, Van Kaanders JHAM et al (2007) Reduced late rectal mucosal changes after prostate three-dimensional conformal radiotherapy with endorectal balloon as observed in repeated endoscopy. Int J Radiat Oncol Biol Phys 67:799–811CrossRef
15.
Teh BS, Lewis GD, Mai W, Pino R, Ishiyama H, Butler EB (2018) Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer. Cancer Commun 38(1):11. https://​doi.​org/​10.​1186/​s40880-018-0281-4 (PMID: 29764515; PMCID: PMC5993141)CrossRef
16.
Mahdavi SR, Ghaffari H, Mofid B, Rostami A, Reiazi R, Janani L (2019) Rectal retractor application during image-guided dose-escalated prostate radiotherapy. Strahlenther Onkol 195:923–933CrossRef
17.
Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie XJ et al (2011) Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 29:2020–2026CrossRef
18.
Kim DWN, Cho LC, Straka C, Christie A, Lotan Y, Pistenmaa D et al (2014) Predictors of rectal tolerance observed in a dose-escalated phase 1–2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 89:509–587CrossRef
19.
Jorgo K, Polgar C, Major T, Stelczer G, Herein A, Pocza T et al (2020) Acute and late toxicity after moderate hypofractionation with simultaneous integrated boost (SIB) radiation therapy for prostate cancer. A single institution, prospective study. Pathol Oncol Res 26:905–912CrossRef
20.
Swanson GP, Stathakis S (2011) Rectal dose constraints for intensity modulated radiation therapy of the prostate. Am J Clin Oncol 34:188–195CrossRef
Metadata
Title
In reply to Afkhami Ardekani M et al.
Authors
Franco Campostrini, MD
Alberto Buffoli, MD
Federica Foscarini, MD
Manuel Zorzi, MD
Publication date
01-04-2021
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 4/2021
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-020-01720-x

Other articles of this Issue 4/2021

Strahlentherapie und Onkologie 4/2021 Go to the issue

Original Article

Matched-pair dosimetric comparison of cardiac radiation exposure between deep-inspiration breath-hold whole-breast radiation therapy with Active Breathing Coordinator and interstitial multicatheter high-dose-rate brachytherapy as accelerated partial breast irradiation in adjuvant treatment of left-sided breast cancer after breast-conserving surgery

Literatur kommentiert

Kurative Strahlentherapie von Oligometastasen: Langzeitergebnisse der SABR-COMET-Studie

Original Article

Hybrid volumetric modulated arc therapy for hypofractionated radiotherapy of breast cancer: a treatment planning study

Literatur kommentiert

Vulnerabilitäten bei Radiomics: Warum die populärste Radiomics-Signatur unbemerkt das Tumorvolumen gemessen hat

Review Article

Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: Considerations regarding FAST and FAST-Forward

Original Article

Quality of life and fatigue before and after radiotherapy in breast cancer patients